SG10201605644WA - Parenteral norovirus vaccine formulations - Google Patents
Parenteral norovirus vaccine formulationsInfo
- Publication number
- SG10201605644WA SG10201605644WA SG10201605644WA SG10201605644WA SG10201605644WA SG 10201605644W A SG10201605644W A SG 10201605644WA SG 10201605644W A SG10201605644W A SG 10201605644WA SG 10201605644W A SG10201605644W A SG 10201605644WA SG 10201605644W A SG10201605644W A SG 10201605644WA
- Authority
- SG
- Singapore
- Prior art keywords
- vaccine formulations
- norovirus vaccine
- parenteral
- parenteral norovirus
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161506447P | 2011-07-11 | 2011-07-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201605644WA true SG10201605644WA (en) | 2016-09-29 |
Family
ID=47506489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201605644WA SG10201605644WA (en) | 2011-07-11 | 2012-07-11 | Parenteral norovirus vaccine formulations |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US9801934B2 (en) |
| EP (3) | EP3299030B1 (en) |
| JP (2) | JP6208659B2 (en) |
| KR (1) | KR102096937B1 (en) |
| CN (3) | CN108567975A (en) |
| AU (2) | AU2012282658B2 (en) |
| BR (1) | BR112014000656A2 (en) |
| CA (1) | CA2841356C (en) |
| CL (1) | CL2014000082A1 (en) |
| CR (2) | CR20190540A (en) |
| DK (1) | DK3299030T3 (en) |
| DO (2) | DOP2014000004A (en) |
| EA (3) | EA035442B1 (en) |
| EC (1) | ECSP14013201A (en) |
| ES (2) | ES2926487T3 (en) |
| GE (1) | GEP201706668B (en) |
| HK (3) | HK1198136A1 (en) |
| IL (1) | IL230356B (en) |
| MA (1) | MA35414B1 (en) |
| MX (1) | MX356586B (en) |
| MY (1) | MY170746A (en) |
| PE (1) | PE20140845A1 (en) |
| PH (1) | PH12018501515B1 (en) |
| PL (2) | PL2731621T3 (en) |
| SG (1) | SG10201605644WA (en) |
| TN (1) | TN2014000008A1 (en) |
| UA (1) | UA117732C2 (en) |
| WO (1) | WO2013009849A1 (en) |
| ZA (2) | ZA201401012B (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007303608B2 (en) | 2006-09-29 | 2013-05-02 | Takeda Vaccines, Inc. | Norovirus vaccine formulations |
| KR20100083150A (en) | 2007-09-18 | 2010-07-21 | 리고사이트 파머슈티컬즈 인코퍼레이티드 | Method of conferring a protective immune response to norovirus |
| US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
| EA035442B1 (en) | 2011-07-11 | 2020-06-17 | Такеда Вэксинс, Инк. | Compositions comprising a buffer, vaccines that comprise compositions comprising a buffer and methods of use thereof |
| EP3052631B1 (en) | 2013-10-03 | 2019-08-07 | Takeda Vaccines, Inc. | Methods of detection and removal of rhabdoviruses from cell lines |
| WO2015093452A1 (en) | 2013-12-16 | 2015-06-25 | 武田薬品工業株式会社 | Microneedle |
| CN107184970A (en) * | 2017-02-16 | 2017-09-22 | 北京生物制品研究所有限责任公司 | Oral norovirus subunit vaccine and LT as the vaccine adjuvant purposes |
| GB201703644D0 (en) | 2017-03-07 | 2017-04-19 | Elopak As | Improvements in or relating to toller mounting arrangements |
| EP3624851A1 (en) * | 2017-05-15 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| US11633467B2 (en) | 2018-02-15 | 2023-04-25 | Icon Genetics Gmbh | Immunogenic composition and vaccine for generating an immune response to norovirus |
| US20210121511A1 (en) * | 2018-05-29 | 2021-04-29 | Unm Rainforest Innovations | Virus-like particle compositions and methods of using same |
| CN109265542B (en) * | 2018-09-27 | 2021-06-15 | 国药中生生物技术研究院有限公司 | Antibody specifically binding norovirus GII.4 genotype VP1 protein or VLP, and preparation method and application thereof |
| AR117462A1 (en) * | 2018-12-20 | 2021-08-04 | Takeda Vaccines Inc | VACCINE AGAINST NOROVIRUS, FORMULATIONS AND METHODS |
| WO2021140524A1 (en) | 2020-01-08 | 2021-07-15 | Bharat Biotech International Limited | Viral vaccine compositions and methods of preparations thereof |
| CA3213547A1 (en) | 2021-03-29 | 2022-10-06 | Naoshi Fukushima | Peptide of norovirus origin, polynucleotide, antibody, composition, method for identifying neutralizing epitope for norovirus |
| JP2024519800A (en) | 2021-05-21 | 2024-05-21 | タケダ ワクチン，インコーポレイテッド | Solid composition, freeze-drying method and glass vial |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6572862B1 (en) | 1989-11-08 | 2003-06-03 | Baylor College Of Medicine | Methods and reagents to detect and characterize Norwalk and related viruses |
| WO1992016543A1 (en) | 1991-03-25 | 1992-10-01 | Genelabs Incorporated | NORWALK VIRUS HUMAN GASTROENTERITIS AGENT AND MOLECULAR CLONING OF CORRESPONDING cDNAs |
| WO1993021325A1 (en) | 1992-04-08 | 1993-10-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Wild-type measles virus glycoproteins: vaccine and detection method therefor |
| JPH08500250A (en) | 1992-09-07 | 1996-01-16 | ベイラー・カレッジ・オブ・メディシン | Methods and reagents for detecting and characterizing Norwalk and related viruses |
| HU219056B (en) | 1993-03-23 | 2001-02-28 | Smithkline Beecham Biologicals Sa | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a |
| US5788970A (en) | 1994-03-29 | 1998-08-04 | The University Of Maryland College Park | Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon |
| MXPA96005662A (en) | 1994-05-16 | 2004-08-19 | Merck & Co Inc | Papillomavirus vaccines. |
| US5645051A (en) | 1995-04-21 | 1997-07-08 | Dura Pharmaceuticals, Inc. | Unit dose dry powder inhaler |
| US5861241A (en) | 1995-08-16 | 1999-01-19 | University Of Massachusetts | Monoclonal antibodies for detecting Norwalk virus |
| GB9525083D0 (en) | 1995-12-07 | 1996-02-07 | Danbiosyst Uk | Vaccine compositions |
| US5834015A (en) * | 1996-09-11 | 1998-11-10 | Albany Medical College | Protein-lipid vesicles and autogenous vaccine comprising the same |
| US5953727A (en) | 1996-10-10 | 1999-09-14 | Incyte Pharmaceuticals, Inc. | Project-based full-length biomolecular sequence database |
| US6491919B2 (en) | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
| PT973546E (en) | 1997-04-08 | 2004-06-30 | Merck & Co Inc | STABILIZED FORMULATIONS OF HUMAN PAPILOMA VIRUS |
| EP0980257A1 (en) | 1997-05-01 | 2000-02-23 | Chiron Corporation | Use of virus-like particles as adjuvants |
| US20040265377A1 (en) | 1997-10-27 | 2004-12-30 | Harry Seager | Solid dispersing vaccine composition for oral delivery |
| PL347472A1 (en) | 1998-08-14 | 2002-04-08 | Merck & Co Inc | Process for purifying human papillomavirus virus-like particles |
| EP1140161B1 (en) | 1998-12-17 | 2006-04-19 | Merck & Co., Inc. | Synthetic virus-like particles with heterologous epitopes |
| DK1150712T3 (en) * | 1999-02-05 | 2009-02-02 | Merck & Co Inc | Human papillomavirus vaccine formulations |
| KR100762092B1 (en) | 1999-06-22 | 2007-10-04 | 국립감염증연구소장이 대표하는 일본국 | Srsv detection kit |
| JP2002020399A (en) | 2000-07-10 | 2002-01-23 | Osaka Prefecture | Monoclonal antibody recognizing norwalk virus(nv) |
| GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| WO2003068933A2 (en) | 2002-02-14 | 2003-08-21 | Novavax, Inc. | Optimization of gene sequences of virus-like particles for expression in insect cells |
| GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| GB0206359D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| WO2003087327A2 (en) | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Preservation of bioactive materials by freeze dried foam |
| GB0302218D0 (en) | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
| AU2003237528A1 (en) | 2002-06-07 | 2003-12-22 | Kentucky Bioprocessing, Llc | Flexible vaccine assembly and vaccine delivery platform |
| AU2003242742B2 (en) | 2002-06-20 | 2009-04-30 | Cytos Biotechnology Ag | Packaged virus-like particles for use as adjuvants: method of preparation and use |
| DE602004020189D1 (en) | 2003-01-30 | 2009-05-07 | Novartis Vaccines & Diagnostic | ADJUVANT INFLUENZA VACCINE |
| WO2004073652A2 (en) | 2003-02-20 | 2004-09-02 | Becton Dickinson And Company | Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination |
| US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| US7879338B2 (en) | 2003-07-21 | 2011-02-01 | Boyce Thompson Institute For Plant Research | Vectors and methods for immunization against norovirus using transgenic plants |
| US20050152911A1 (en) | 2003-09-24 | 2005-07-14 | Montana State University | Norovirus monoclonal antibodies and peptides |
| US7795242B2 (en) | 2003-10-15 | 2010-09-14 | The Brigham And Women's Hospital, Inc. | Methods and compositions for immunomodulation |
| US20050215501A1 (en) | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
| FR2863890B1 (en) | 2003-12-19 | 2006-03-24 | Aventis Pasteur | IMMUNOSTIMULATING COMPOSITION |
| US7481997B1 (en) | 2004-02-12 | 2009-01-27 | Montana State University | Snow mountain virus genome sequence, virus-like particles and methods of use |
| US20050260225A1 (en) | 2004-05-18 | 2005-11-24 | Goldberg Joanna B | Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens |
| CU23496A1 (en) | 2004-09-03 | 2010-02-23 | Ct Ingenieria Genetica Biotech | VACCINE COMPOSITION AGAINST THE VIRUS OF HEPATITIS C |
| KR101501162B1 (en) | 2004-10-20 | 2015-03-16 | 사노피 파스테르 바이오로직스, 엘엘씨 | Vaccines against Japanese Encephalitis Virus and West Nile Virus |
| GB0428394D0 (en) | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
| CN101128216A (en) | 2005-01-05 | 2008-02-20 | 费城健康和教育公司 | Delivery vehicles, bioactive substances and viral vaccines |
| US8168771B2 (en) | 2005-01-31 | 2012-05-01 | The Johns Hopkins University | Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants |
| CN101203529A (en) | 2005-02-18 | 2008-06-18 | 诺华疫苗和诊断公司 | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
| ZA200707413B (en) | 2005-03-18 | 2009-01-28 | Cytos Biotechnology Ag | Cat allergen fusion proteins and uses thereof |
| EP1885394A4 (en) | 2005-06-01 | 2009-10-21 | Dow Global Technologies Inc | Production of multivalent virus like particles |
| EP1736538A1 (en) | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
| WO2007081447A2 (en) | 2005-11-22 | 2007-07-19 | Novartis Vaccines And Diagnostics, Inc. | Norovirus and sapovirus antigens |
| JP2007145775A (en) | 2005-11-29 | 2007-06-14 | Falco Life Science:Kk | Method for detecting norovirus gi in high sensitivity |
| US20080029915A1 (en) * | 2006-08-02 | 2008-02-07 | Courtoy Nv | Rotary tablet press |
| AU2007303608B2 (en) | 2006-09-29 | 2013-05-02 | Takeda Vaccines, Inc. | Norovirus vaccine formulations |
| NZ577405A (en) | 2006-12-06 | 2012-08-31 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
| US8481693B2 (en) * | 2007-03-14 | 2013-07-09 | Takeda Vaccines (Montana), Inc. | Virus like particle purification |
| WO2009033229A1 (en) | 2007-09-12 | 2009-03-19 | Australian Centre For Plant Functional Genomics Pty Ltd | Plant seed active transcriptional control sequences |
| KR20100083150A (en) * | 2007-09-18 | 2010-07-21 | 리고사이트 파머슈티컬즈 인코퍼레이티드 | Method of conferring a protective immune response to norovirus |
| US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
| AU2009279456B2 (en) | 2008-08-08 | 2015-02-05 | Takeda Vaccines, Inc. | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
| CA2750321A1 (en) * | 2009-01-22 | 2010-07-29 | Pharmathene, Inc. | Stable vaccine compositions and methods of use |
| US20120093859A1 (en) * | 2009-02-10 | 2012-04-19 | Novartis Ag | Influenza vaccine regimens for pandemic-associated strains |
| US20110070260A1 (en) | 2009-09-09 | 2011-03-24 | Baric Ralph S | Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use |
| SG182636A1 (en) | 2010-01-21 | 2012-08-30 | Ligocyte Pharmaceuticals Inc | Targeted heterologous antigen presentation on calicivirus virus-like particles |
| EP2575876B1 (en) * | 2010-05-26 | 2017-12-06 | Selecta Biosciences, Inc. | Multivalent synthetic nanocarrier vaccines |
| EA035442B1 (en) | 2011-07-11 | 2020-06-17 | Такеда Вэксинс, Инк. | Compositions comprising a buffer, vaccines that comprise compositions comprising a buffer and methods of use thereof |
| JOP20130186B1 (en) | 2012-06-22 | 2021-08-17 | Takeda Vaccines Montana Inc | Purification of virus like particles |
| EP4253412A3 (en) | 2015-12-16 | 2023-11-22 | The Walter and Eliza Hall Institute of Medical Research | Inhibition of cytokine-induced sh2 protein in nk cells |
| AU2017346885B2 (en) | 2016-10-18 | 2021-10-21 | Intima Bioscience, Inc. | Tumor infiltrating lymphocytes and methods of therapy |
| MX2020011697A (en) | 2018-05-03 | 2020-12-10 | Univ Texas | Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade. |
| EP3840778A1 (en) | 2018-08-20 | 2021-06-30 | Takeda Vaccines, Inc. | Vlp formulations |
| AR117462A1 (en) | 2018-12-20 | 2021-08-04 | Takeda Vaccines Inc | VACCINE AGAINST NOROVIRUS, FORMULATIONS AND METHODS |
| WO2020168300A1 (en) | 2019-02-15 | 2020-08-20 | Editas Medicine, Inc. | Modified natural killer (nk) cells for immunotherapy |
-
2012
- 2012-07-11 EA EA201792407A patent/EA035442B1/en not_active IP Right Cessation
- 2012-07-11 ES ES17199372T patent/ES2926487T3/en active Active
- 2012-07-11 WO PCT/US2012/046222 patent/WO2013009849A1/en active Application Filing
- 2012-07-11 PE PE2014000054A patent/PE20140845A1/en active IP Right Grant
- 2012-07-11 KR KR1020147003571A patent/KR102096937B1/en active IP Right Grant
- 2012-07-11 CA CA2841356A patent/CA2841356C/en active Active
- 2012-07-11 PL PL12811916T patent/PL2731621T3/en unknown
- 2012-07-11 EP EP17199372.8A patent/EP3299030B1/en active Active
- 2012-07-11 CN CN201810373895.1A patent/CN108567975A/en active Pending
- 2012-07-11 EA EA201490258A patent/EA029470B1/en not_active IP Right Cessation
- 2012-07-11 ES ES12811916.1T patent/ES2656527T3/en active Active
- 2012-07-11 BR BR112014000656A patent/BR112014000656A2/en not_active Application Discontinuation
- 2012-07-11 MX MX2014000411A patent/MX356586B/en active IP Right Grant
- 2012-07-11 CR CR20190540A patent/CR20190540A/en unknown
- 2012-07-11 GE GEAP201213384A patent/GEP201706668B/en unknown
- 2012-07-11 EP EP22176978.9A patent/EP4112074A1/en active Pending
- 2012-07-11 EP EP12811916.1A patent/EP2731621B1/en active Active
- 2012-07-11 CN CN201280043691.2A patent/CN103874507A/en active Pending
- 2012-07-11 DK DK17199372.8T patent/DK3299030T3/en active
- 2012-07-11 CN CN201510262891.2A patent/CN105031637A/en active Pending
- 2012-07-11 SG SG10201605644WA patent/SG10201605644WA/en unknown
- 2012-07-11 PL PL17199372.8T patent/PL3299030T3/en unknown
- 2012-07-11 AU AU2012282658A patent/AU2012282658B2/en active Active
- 2012-07-11 EA EA202090699A patent/EA202090699A3/en unknown
- 2012-07-11 JP JP2014520273A patent/JP6208659B2/en active Active
- 2012-07-11 MY MYPI2014000073A patent/MY170746A/en unknown
- 2012-11-07 UA UAA201401321A patent/UA117732C2/en unknown
-
2013
- 2013-03-15 US US13/840,403 patent/US9801934B2/en active Active
-
2014
- 2014-01-07 TN TNP2014000008A patent/TN2014000008A1/en unknown
- 2014-01-07 IL IL230356A patent/IL230356B/en active IP Right Grant
- 2014-01-10 DO DO2014000004A patent/DOP2014000004A/en unknown
- 2014-01-10 CL CL2014000082A patent/CL2014000082A1/en unknown
- 2014-02-06 MA MA36741A patent/MA35414B1/en unknown
- 2014-02-10 ZA ZA2014/01012A patent/ZA201401012B/en unknown
- 2014-02-11 EC ECSP14013201 patent/ECSP14013201A/en unknown
- 2014-02-11 CR CR20140069A patent/CR20140069A/en unknown
- 2014-11-21 HK HK14111772.5A patent/HK1198136A1/en unknown
- 2014-12-18 HK HK14112697.5A patent/HK1199202A1/en unknown
- 2014-12-18 HK HK16102061.2A patent/HK1215154A1/en unknown
-
2015
- 2015-02-09 ZA ZA2015/00915A patent/ZA201500915B/en unknown
- 2015-02-19 AU AU2015200836A patent/AU2015200836B2/en active Active
- 2015-07-10 US US14/796,614 patent/US9867876B2/en active Active
-
2017
- 2017-05-02 JP JP2017091755A patent/JP6613259B2/en active Active
- 2017-12-08 US US15/836,030 patent/US10675341B2/en active Active
-
2018
- 2018-07-06 PH PH12018501515A patent/PH12018501515B1/en unknown
-
2020
- 2020-06-05 US US16/894,291 patent/US11701420B2/en active Active
-
2022
- 2022-02-04 DO DO2022000030A patent/DOP2022000030A/en unknown
-
2023
- 2023-05-24 US US18/322,679 patent/US20230338503A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263973B (en) | Protein-polymer-drug conjugates | |
| ZA201500915B (en) | Parenteral norovirus vaccine formulations | |
| HK1196257A1 (en) | P97-antibody conjugates p97- | |
| IL228404A0 (en) | Anitbody-drug conjugates | |
| EP2904544A4 (en) | Enhanced bundle adjustment techniques | |
| IL231043A (en) | Vaccine | |
| EP2755680A4 (en) | Particluate vaccine formulations | |
| EP2660100A4 (en) | Headrest | |
| GB201119999D0 (en) | Vaccine | |
| EP2763699A4 (en) | Vaccine | |
| EP2771453A4 (en) | Diatom-based vaccines | |
| ZA201306245B (en) | Combination vaccines | |
| GB201120109D0 (en) | Malaria vaccine | |
| GB201120000D0 (en) | Vaccine | |
| GB201110278D0 (en) | Formulations | |
| HK1154459A2 (en) | Headrest | |
| GB201121647D0 (en) | Vaccine | |
| GB201108256D0 (en) | Vaccine | |
| GB201108982D0 (en) | Vaccines | |
| GB201108984D0 (en) | Vaccines | |
| GB201108986D0 (en) | Vaccines | |
| GB201111578D0 (en) | Pharmeutical formulations | |
| GB201111013D0 (en) | Formulations | |
| GB201107626D0 (en) | Formulations | |
| GB201107627D0 (en) | Formulations |